Skip to main content
OpenTrials
Completed

NCT Number: NCT06685341

PK/PD Study of YZJ-1139

Primary Objective： To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Insomnia Dyssomnias Mental Disorders Nervous System Diseases Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Beijing Tiantan Hospital, Capital Medical University

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Young adults and elderly Chinese healthy subjects, both male and female;
  • Age: [young adult group] 18-45 years old (including the threshold value); [Elderly group]65~75 years old (including the cut-off value);
  • Body weight [only for young adults]: ≥50kg, BMI: 18~28kg/m2 (including the threshold value);
  • Understand and sign the informed consent to participate in the study.

Exclusion criteria

  • History of heart, liver, lung, kidney, digestive tract, blood system, neuropsychiatric system and other diseases, including anxiety and depression, that researchers deem clinically significant;
  • Comprehensive physical examination, neurological examination, laboratory examination, ECG examination, etc. indicate that the subject has abnormalities that are judged by the researcher as clinically significant;
  • Poor compliance with the pharmacodynamics training before administration;
  • Have taken any medication in the two weeks prior to study administration, and the investigator judges it may affect the evaluation results;
  • History of food and drug allergy or allergic reaction that the researcher determines to be clinically significant;
  • Serological examination (HBsAg, anti-HCV, anti-HIV, TP-Ab) with positive results;
  • History of alcohol or drug abuse within the year prior to study administration that the investigators believe may have affected the results assessed in this study;
  • Frequent (> 1 time per month) use of hypnotic drugs, and screening and baseline benzodiazepine urine screening positive;
  • Participants who need to work night shifts, stay up late, or stay at least 3 time zones away from the study site within 2 weeks before and during the study;
  • Subjects who could not maintain a regular sleep and rest schedule (get up at 6-8 am and go to sleep at 10-12 PM) within 1 week before and during the study and who were judged by the investigator to be likely to affect the results of this study;
  • Those who could not quit smoking and alcohol drinking as required during the study period or whose carbon monoxide breath test detected >7 ppm during the screening period (further confirmation by urine cotinine test if deemed necessary by the investigators);
  • Participants who have participated in any drug clinical trial as a subject within 3 months prior to study administration;
  • Patients who donated blood or blood products ≥400 mL or 2 units within three months prior to drug administration;
  • Those who do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or to avoid strenuous exercise, or to avoid other factors affecting the absorption, distribution, metabolism or excretion of drugs within 24 hours before and during the trial;
  • Don't agree or is unable to refrain from eating grapefruit or other related tropical fruits and beverages and from using St. John's Wort during the 24 hours prior to the first dose and during the study period;
  • Women who are pregnant or nursing, or who test positive for serum HCG before trial administration, or who cannot/do not use investigator-approved contraception during the study as required;
  • Those with abnormal cognitive function assessment (MMSE less than 26 points) and judged by the researchers to be clinically significant;
  • Subjects deemed unsuitable for this clinical study by the investigator.

Treatment and study plan

YZJ-1139

Drug

YZJ-1139

Placebo

Drug

Oral tablet

zolpidem

Drug

Oral tablet

Primary outcomes

  1. Cmax of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Cmax is defined as the maximum concentration of drug

  2. AUCinf of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    AUCinf is defined as the concentration of drug extrapolated to infinite time

  3. AUClast of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    AUClast is defined as the concentration of drug from time zero to the last observable concentration

  4. Tmax of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Tmax is defined as the time (observed time point) of Cmax

  5. t1/2 of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

  6. CL/F of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    CL/F is defined as the apparent oral clearance following administration of the drug

  7. Vz/F of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Vz/F is defined as the apparent volume of distribution of the drug

  8. Left and right saccade peak velocity (SPV) of Eye Movements

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue.

    Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

  9. left and right saccade accuracy rate (SacAcc) of Eye Movements

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue.

    Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

  10. Left and right saccade eye movement response time (SacRT) of Eye Movements

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue.

    Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

  11. Smooth eye movement to the left and right (Smooth) of Eye Movements

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue.

    Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

  12. Body Sway

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The subject takes off their shoes, spreads their feet shoulder-width apart, and stands on a flat ground 120 cm away from the measuring device. They close their eyes and stand for 2 minutes, and the test measures the body sway amplitude (mm) of the subject during the 2-minute closed-eye period. The test evaluates the subject's postural balance

  13. Simple response time of Choice Reaction Time Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test lasts for 1 minute. During the test, there is a vertical line in the center of the screen. On both sides of the screen, random "left" or "right" words will appear. The participants are required to ignore the word meanings and click the "right" or "left" key based on the word's position.

  14. Simple response accuracy rate of Choice Reaction Time Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test lasts for 1 minute. During the test, there is a vertical line in the center of the screen. On both sides of the screen, random "left" or "right" words will appear. The participants are required to ignore the word meanings and click the "right" or "left" key based on the word's position.

  15. Selective response time of Choice Reaction Time Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    During the test, there was a dividing line in the middle of the screen. During the test, the word "left" or "right" appeared randomly on both sides of the screen. Subjects were asked to ignore the position of the word and click the key "right" or "left" according to the meaning of the word.

  16. Selective response accuracy rate of Choice Reaction Time Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    During the test, there was a dividing line in the middle of the screen. During the test, the word "left" or "right" appeared randomly on both sides of the screen. Subjects were asked to ignore the position of the word and click the key "right" or "left" according to the meaning of the word.

  17. The average reaction time for correct responses of Digit Symbol Substitution Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

  18. The number of correct responses of Digit Symbol Substitution Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

  19. The average reaction time for incorrect responses of Digit Symbol Substitution Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

  20. The number of incorrect responses of Digit Symbol Substitution Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

  21. The number of non-responses of Digit Symbol Substitution Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

  22. Immediate recall of Word Recall Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    About 1-2 hours after dosing， First, the subjects were shown 20 unrelated words, each word for a few seconds, and then the subjects were asked to immediately recall the words they just saw.

    The number of correct words in instantaneous recall was recorded respectively

  23. Delayed recall of Word Recall Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    About 1-2 hours later, the subjects were allowed to freely recall the words again, which was delayed recall; The number of correct words in delayed recall was recorded respectively

  24. Delayed recognition of Word Recall Test

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

    The subjects were then presented with 40 words (of which 20 were previously presented words and 20 were confounding words), and were asked to answer one by one whether they were the words they had just seen.

    The number of correct words in delayed extraction was recorded respectively

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: From Day 1 to Day 2 post single dose；up to 4 weeks

Sponsors and collaborators

Lead sponsor

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Zolpidem and Placebo-Controlled, 4-Way-Period Crossover, Pharmacokinetics and Pharmacodynamics Study of YZJ-1139 Single-Dose Oral in Healthy Young and Elderly Chinese Subjects

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Nov 12, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.